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Cyclooxygenase-2 (COX-2) is selectively overexpressed in colorectal tumours. The mechanism of COX-2 induction is not fully
understood, but requires de novo messenger RNA and protein synthesis, indicating regulation at the transcriptional level. Sequence
analysis of the 50-flanking region of the COX-2 gene shows two nuclear factor-kB (NF-kB) sites. Inhibition of this protein in model
cell culture systems attenuates COX-2 expression and implies that NF-kB plays an important role in COX-2 induction. We
measured COX-2, NF-kB and IkB kinase a (IKKa) protein expression in matched colonic biopsy samples comprising both nontumour
and adjacent tumour tissue from 32 colorectal cancer patients using immunohistochemistry. There was none or very little expression
of COX-2, NF-kB and IKKa in non-neoplastic colon epithelial cells, while the expression of all three of these proteins was significantly
increased (Po0.05, Wilcoxon’s signed rank test) in adjacent cancerous cells. Moreover, all three proteins were found to be
coexpressed in the neoplastic epithelium, with the expression of COX-2 and NF-kB highly correlated (Pearson’s correlation,
Po0.005). There was no apparent correlation between enhanced COX-2, NF-kB or IKKa expression and tumour Dukes’ stages.
Our results are compatible with the hypothesis that IKKa and NF-kB are involved in COX-2 induction in these tumours and the lack
of association between COX-2 expression and severity of disease as measured by Dukes’ stage is consistent with the proposal that
COX-2 expression is an early postinitiation event.
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Cyclooxygenases (COX) are intracellular proteins that catalyse the
rate-limiting step in the synthesis of prostaglandins (PGs), a potent
group of autocrine and paracrine lipid mediators (Mitchell et al,
1995; Smith et al, 1996; Chen et al, 2000) that are implicated in
many normal cellular and pathophysiological processes (Mitchell
et al, 1995; Portanova et al, 1996; Smith et al, 1996; Chen et al,
2000). Two forms of COX have been identified to date: the
constitutively expressed form COX-1, and the inducible form COX-
2. The role of COX-2 has been previously studied in colorectal
cancer, and shown to be expressed in adenomas and carcinomas
(Eberhart et al, 1994; Kargman et al, 1995; Sano et al, 1995;
Dimberg et al, 1999; Cianchi et al, 2001; Denkert et al, 2001). COX-
2 is believed to play an important role in colon carcinogenesis and
several mechanisms could account for the link between the activity
of COX-2 and carcinogenesis, including activation of procarcino-
gens (Wiese et al, 2001); production of PGs that can promote
angiogenesis (Tsujji et al, 1998), inhibit immune surveillance and
increase cell proliferation (Sheng et al, 1998); and direct inhibition
of cell apoptosis (Tsujji and DuBois, 1997).
The mechanism of COX-2 induction in colon cancer is not fully
understood, although it is known that induction requires messenger
RNA and protein synthesis (Hempel et al,1 9 9 4 ) ,i n d i c a t i n g
regulation at the transcriptional level. The COX-2 gene can be
induced by a wide variety of stimuli including oncogenic viruses,
growth factors, cytokines and tumour promoters. Overexpression of
COX-2 caused by hypoxia in human umbilical vein endothelial cells
and in human alveolar epithelial cells, and by interleukin-1 (IL-1) in
rheumatoid synoviocytes has been shown to be mediated by the
nuclear factor-kB( N F - kB). Recently, inhibition of this latter
pathway in vitro by curcumin (an inhibitor of NF-kB activation)
has been shown to attenuate COX-2 expression in colon cells
(Plummer et al, 1999), indicating that NF-kB may play an important
role in COX-2 induction. Should this be the case in neoplastic cells,
then the NF-kB control of COX-2 expression would be important in
the development and progression of human colorectal carcinoma.
We have therefore examined tissue biopsies obtained from
patients with diagnosed primary colorectal cancer undergoing
surgical treatment for their disease, for differences in the
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sexpression of COX-2 in malignant and adjacent normal epithelial
cells, and for alterations in the expression of the upstream
intracellular proteins that appear to be linked to COX-2 expres-
sion, specifically NF-kB and IkB kinase a (IKKa).
MATERIALS AND METHODS
Patients
Surgical specimens of primary tumours were obtained with
informed consent from 32 patients with histologically verified
colorectal cancer, treated at the Department of Surgery, York
District Hospital, York, UK. Ethical approval for the study was
obtained from the Human Research Ethics Committee at York
District Hospital. Tumours were classified according to the Dukes’
classification (see Table 1). The entire study was carried out blind
using coded tissue sections.
Tissue specimens
Tissue samples taken at operation for histopathological confirma-
tion of disease were fixed in 4% buffered formaldehyde and
embedded in paraffin wax; sections surplus to pathology require-
ments were made available for this study. For 24 patients, tissue
sections of both normal and malignant colon or rectum were
provided (matched samples), while for the other eight patients
only sections of malignant tissue were available. Only matched
tissue was used for statistical analysis.
Antibodies
The goat and rabbit polyclonal immunoglobulins (IgGs) for anti-
human COX-2 and NF-kB-p65 were as previously described
(Maiho ¨fner et al, 2000). The rabbit polyclonal IgG for anti-human
IKKa was obtained from Santa Cruz Biotechnology Inc. (Santa
Cruz, USA).
Immunohistochemistry
The expression of COX-2, NF-kB and IKKa in normal and
malignant human colon epithelial cells was determined using a
modified avidin/biotin immunohistochemistry procedure (Goggi
et al, 1986). In preliminary experiments, each of the immunohisto-
chemistry assays was optimised using a range of antisera dilutions
(1/200–1/5000). For each assay, the negative control antisera
(preimmune sera) were confirmed negative for staining at the
dilution optimised for the primary antibody and blocking peptides
(Santa Cruz Biotechnology Inc.) confirmed specificity. The
dilutions used were 1/1500, 1/1000 and 1/800 for the anti-COX-2,
NF-kB and IKKa antibodies, respectively. The sections were
deparaffinised and rehydrated through xylene and a series of
graded alcohol solutions. Endogenous peroxidase activity was
blocked by immersing the sections into a solution of 3% hydrogen
peroxide in distilled water for 30min at room temperature, and
then rinsed in cold running tap water for 10min. Incubating the
sections with 5% normal swine serum for 30min at room
temperature reduced nonspecific background staining. Sections
were then washed twice with phosphate-buffered saline (PBS)
(5min per wash) and 1ml of either the primary antibody or the
normal goat or rabbit IgGs (negative control) was applied to each
section, and left at 41C overnight. The next day, the slides were
washed twice with PBS (5min per wash), and then incubated with
the secondary antibody solution (Biotinylated Swine anti-goat,
mouse, rabbit immunoglobulin; 1/150 dilution; 1ml per section)
for 1h at room temperature. After being washed twice with PBS
(5min per wash), they were incubated with the StreptABComplex
Table 1 Patient demographic information
Patient
code Age
a Sex
Tumour
site
Dukes’
stage Drug history
Tobacco
use Alcohol
b
3053 72 M Colon B None No 8+
3501 68 M Colon C NA No NA
3506 66 F Colon C1 5-Fluorouracil, Enalapril No 0
3507 69 M Rectum C Co-codamol No 1–7
3509 49 F Colon B NA Yes NA
3510 63 F Rectum NA NA No NA
3512 52 M Rectum C1 Adalat No 1–7
3515 75 M Colon C NA No NA
3516 68 M Colon B Atenolol, Prednisolone, Warfarin, Diltiazem, Isosorbide, Gliclazide, Co-danthramer No 1–7
3517 69 M Rectum C1 Atenolol No 8+
3518 70 F Rectum B Lithium, Thyroxine No 8+
3519 72 M Rectum B Captopril, Naproxen, Allopurinol, Isosorbide, Frusemide, Atenolol, Prochlorperazine No 1–7
3521 78 M Colon A NA No NA
3522 56 M Colon A None No 8+
3524 76 M Colon A None No 1–7
3525 44 M Colon C NA No NA
3528 58 F Colon NA None No 0
3529 61 F Rectum A NA No NA
3531 66 F Colon B None No 0
3532 54 M Rectum C1 None No 1–7
3533 49 M Colon B None No 8+
3534 73 F Colon B NA Yes NA
3535 52 M Rectum B None No 8+
3536 68 M Colon B Salbutamol, Ferrous sulphate No 0
3537 63 F Rectum A Salbutamol, Beclomethasone, Bendrofluazide No 1–7
3538 56 M Colon C Losec No 8+
3540 68 M Rectum B Sotalol, Aspirin No 8+
3542 80 F Rectum B None No 0
3548 59 M Rectum C1 None No 8+
3550 66 M Rectum NA None Yes 8+
NA¼Not available.
aAge in years.
bAlcohol consumption in units per week (1 unit¼half a pint of beer or one glass of wine or one shot of spirits).
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ssolution (1ml per section) for 1h at room temperature, washed
twice with PBS (5min per wash) and immersed into the substrate
(300ml PBS, 90ml hydrogen peroxide and 2.5ml 3,3-diaminoben-
zidine) for 3min, and then rinsed with PBS and cold running tap
water (5min each). Sections were then successively immersed into
haematoxylin, acid alcohol and Scott’s tap water to counterstain.
Finally, the sections were dehydrated by successive immersion into
70% ethanol, 100% ethanol twice and xylene twice and mounted.
Immunohistochemical evaluation
Processed specimens were scored under the light microscope and
the extent and intensity of staining with COX-2, NF-kB and IKKa
antibodies graded blind using coded slides. In order to assess and
grade intensity and distribution of immunoreactivity in the colonic
epithelium, a scoring method that has been previously described
(Yukawa et al, 1994) was used. The distribution was scored
according to the number of positive cells: none (not stained), 0;
focal (o1/3 of cells stained), 1; multifocal (1/3–2/3 of cells
stained), 2; and diffuse (42/3 stained), 3. The staining intensity
was scored as: none (not stained), 0; mild (between 0 and 2), 1; and
strong, 2. The distribution and intensity scored were added to
produce the following grades for the staining: 0, negative; 2,
intermediate; and 3, 4 and 5, positive. Sections treated with the
normal goat or rabbit IgGs (negative controls) or omitting the
primary antibody were devoid of staining (Figure 1). Positive
staining controls for COX-2 included sections of brain, kidney and
uterus. Representative examples of staining for COX-2 are shown
in Figure 1.
Statistical analysis
The Wilcoxon’s signed rank test was used to compare the scoring
of the respective immunoreactivity for COX-2, NF-kB and IKKa
between malignant and control epithelial tissues. The Pearson
correlation test was used to assess the relation between COX-2
expression and NF-kB and IKKa, and additionally to assess
correlation between COX-2, NF-kB and IKKa and Dukes’ stages.
RESULTS
Expression of COX-2 in normal and malignant colorectal
epithelial cells
Tissue sections of normal and malignant large bowel from
colorectal cancer patients were investigated for COX-2 expression
by immunohistochemistry. There was little cytoplasmic expression
of COX-2 in non-neoplastic colonic and rectal epithelial cells (five
out of 23 patients, mean rating score 0.826), consistent with the
fact that COX-2 is an inducible enzyme. Yet in both colonic and
rectal malignant epithelial cells, there was good COX-2 expression
(17 out of 30 patients, mean rating score 1.913) (Figure 1). The
staining was cytoplasmic and particularly concentrated around the
nucleus, which is consistent with the known localisation of COX
(rough endoplasmic reticulum and inner nuclear membrane). No
staining was observed inside the nuclei of the epithelial cells. In
those non-neoplastic tissue samples in which immunoreactive
staining for COX-2 was detected, a similar pattern of expression
was observed. Moderately and well-differentiated neoplastic
epithelial cells showed significantly higher immunoreactivity than
poorly differentiated tissues. Statistical analysis was applied to
matched (nonmalignant vs malignant tissue from the same patient)
samples (see Figure 2), and demonstrated a significantly higher
rating of the respective intensity scores for colorectal cancer
epithelium compared to control cells (Wilcoxon’s signed rank test;
Po0.027 for COX-2).
Expression of NF-jB-p65 in normal and malignant
colorectal epithelial cells
Tissue sections of normal and malignant large bowel from
colorectal cancer patients were also investigated for NF-kB-p65
expression. The majority of the non-neoplastic colon and rectum
specimens showed either none at all or very little cytoplasmic
expression of NF-kB-p65 (four out of 24 patients, mean rating
score¼0.750), and no staining was observed inside the nuclei
(Figure 1). In contrast, in more than half of the colonic and rectal
malignant epithelial cells there was an observable increase of NF-
kB-p65 expression, which was mainly cytoplasmic but with some
staining observed inside the nuclei (17 out of 32 patients, mean
rating score¼2.083). Moderately and well-differentiated malignant
epithelial cells showed significantly higher immunoreactivity than
poorly differentiated cells. For the matched samples, the majority
of patients had a measurable increase in the expression of
immunoreactive NF-kB-p65 in malignant cells compared to their
matched nonmalignant tissue (13 out of 24 patients). Statistical
analysis (Wilcoxon’s signed rank test) of the matched patient
samples (Figure 2) showed that there was a highly significant
increase in the mean expression of NF-kB-p65 between normal and
malignant colorectal epithelial cells (Po0.027).
Expression of IKKa in normal and malignant colorectal
epithelial cells
There was little expression of immunoreactive IKKa in non-
neoplastic colonic or rectal epithelial cells (1 out of 17 patients,
mean rating score¼0.176), indicating that IKKa is not constitu-
tively expressed in significant amounts in these cells. Nevertheless,
in both colonic and rectal malignant epithelial cells, there was an
increase of IKKa expression compared to non-neoplastic tissue (12
out of 24 patients, mean rating score¼2.059) (Figure 1).
Examination of the matched samples for changes in the expression
of IKKa showed that the majority (10 out of 17 patients) had an
increase in expression in the malignant compared to the
nonmalignant cells. This was statistically significant (Po0.027)
for matched tissue pairs (Figure 2). The IKKa expression was
mainly cytoplasmic, and no staining was observed inside the nuclei
of the epithelial cells. There was a significantly higher immuno-
reactivity of the protein in moderately and well-differentiated
cancerous epithelial cells than in the poorly differentiated cases.
Coexpression of COX-2, NF-jB and IKKa in malignant
colorectal epithelial cells
In order to determine histologically if there was coexpression of
protein in malignant tissue, serial tissue sections were examined
for expression of COX-2, NF-kB and IKKa. In by far the majority
of cases (15 out of 17), a positive level of COX-2 immunoreactivity
in neoplastic tissue was accompanied by positive levels of NF-kB
and/ or IKKa immunoreactivity (Figure 1) supporting the proposal
that the three proteins were coexpressed. This was particularly
evident in moderately to well-differentiated tissues. In agreement
with this histological finding, there was a highly significant
correlation between COX-2 and NF-kB expression in malignant
epithelium (Pearson’s correlation test, two-tailed, Po0.005,
n¼30) (Figure 3). In the case of IKKa immunoreactivity, although
mean expression increased with mean COX-2 expression, a linear
correlation was not evident (Figure 3).
Association between COX-2, NF-jB or IKKa and severity of
colorectal cancer
Comparison of the expression of COX-2, NF-kB or IKKa and
Dukes’ stage showed no significant association (Pearson’s correla-
tion test).
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sDISCUSSION
We found little expression of COX-2 in non-neoplastic colorectal
epithelial cells, reflecting the fact that COX-2 is an inducible
enzyme with low basal expression. However, in both colonic and
rectal malignant epithelial cells, there was a trend for increased
COX-2 expression, which is consistent with previous reports
(Eberhart et al, 1994; Kargman et al, 1995; Sano et al, 1995;
Dimberg et al, 1999; Shattuck-Brandt et al, 1999; Cianchi et al,
2001; Denkert et al, 2001). A similar trend was observed for both
colonic and rectal malignant epithelial cells, with less than half of
the patients showing no expression of COX-2 (13 out of 30
Figure 1 Immunohistochemical localisation of COX-2, NF-kB and IKKa in normal and malignant colonic epithelia from the same patient. The presence of
the immunoreactive protein is indicated by brown staining. (A) Normal and (E) tumour tissue treated with preimmune sera as primary antibody (negative
control); (B) normal and (F) tumour tissue treated with anti-COX-2 as primary antibody; (C) normal and (G) tumour tissue treated with anti-NF-kB
primary antibody; (D) normal and (H) tumour tissue treated with anti-IKKa primary antibody. Insets are higher magnification of the same section.
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spatients), about a third showing some immunoreactive staining
(score 2 or 3) and the rest showing significant expression (score 4
or 5) (6 out of 30 patients). These results suggest that a similar
mechanism of COX-2 induction is involved in both rectal and
colonic malignant epithelial cells. This is in contrast to a recent
Swedish study (Dimberg et al, 1999), in which there was a notable
overexpression of COX-2 protein in tumours located in the rectum,
compared with other locations in the colon, as measured by
Western blotting. However, many other studies have investigated
COX-2 expression in colorectal cancer, and none has reported a
discrepancy in COX-2 expression between colon and rectal
malignant epithelial cells.
NF-kB is an inducible higher eukaryotic transcription factor,
which has a pivotal role in the regulation of the expression of many
genes involved in immune and inflammatory responses (Sha, 1998;
Bowie and O’Neill, 2000), the replication and reactivation of many
viruses, in neuronal development and neurodegeneration, and in
the control of cell proliferation and apoptosis (Baeuerle and
Henkel, 1994; Pahl and Baeuerle, 1995; Baeuerle and Baltimore,
1996; Bowie and O’Neill, 2000). NF-kB can be activated in response
to a broad range of stimuli and conditions, including bacterial and
viral products, inflammatory cytokines such as IL-1 and tumour
necrosis factor (TNF), B- and T-cell mitogens, intracellular stresses
such as endoplasmic reticulum overload, and extracellular stresses
like asbestos fibres, ultraviolet light and cigarette smoke (Baeuerle
and Henkel, 1994; Janssen et al, 1995; Pahl and Baeuerle, 1995;
Shen et al, 1996; O’Neil and Kaltschmidt, 1997; Bowie and O’Neill,
2000). NF-kB is present in the cytoplasm of unstimulated cells in a
latent form, comprising a transcriptionally active dimer bound to
an inhibitory protein, IkB (Sha, 1998). Both NF-kB and IkB exist in
multiple forms (Baeuerle and Baltimore, 1996).
The mechanism by which diverse stimulants activate NF-kB
involves the phosphorylation of IkBa on two serine residues (S32
and S36). This causes the release of the NF-kB dimer, which can
then translocate to the nucleus and activate target genes by binding
with high affinity to kB elements in promoters (Bowie and O’Neill,
2000). To date, two IkB kinases have been identified, termed IKKa
and IKKb (Whiteside and Israel, 1997). These two proteins have
been shown to be activated by inducers of NF-kB, such as IL-1 and
TNF, to phosphorylate S32 and S36 of IkB, and to play a key role in
the activation of NF-kB by these cytokines (Mercurio et al, 1997;
Stancovski and Baltimore, 1997; Bowie and O’Neill, 2000). The
IKKs are part of a larger multiprotein complex called the IKK
signalsome, which contains the IKK complex-associated protein
(IKAP) and IKKg (also called NEMO), which is also crucial for NF-
kB activation (Cohen et al, 1998; Yamaoka et al, 1998; Bowie and
O’Neill, 2000). Many upstream activators and regulators of IKK
activity have been identified, including the NF-kB-inducing kinase
(NIK) (Nakano et al, 1998), protein kinase Cz (PKCz) (Lallena et al,
1999), transforming growth factor b-activated kinase (TAK-1)
(Ninomiya-Tsuji et al, 1999), MEK kinase (MEKK) 1, 2 and 3
(Zhao and Lee, 1999), and S6 kinase (Schouten et al, 1997). NF-kB
can induce the expression of numerous target genes, including
COX-2. In model systems, overexpression of the COX-2 protein
caused by hypoxia in human umbilical vein endothelial cells and
by IL-1 in rheumatoid synoviocytes has been shown to be
mediated by NF-kB (Schmedtje et al, 1997; Chen et al, 2000).
Furthermore, there are two NF-kB consensus sites present in the
promoter region of the human COX-2 gene (Tazawa et al, 1994),
these being the NF-kB-30 site ( 223/ 214) and the NF-kB-50 site
( 447/ 438), indicating that NF-kB may be involved in COX-2
induction (Bowie and O’Neill, 2000).
From the foregoing, there is evidence from model systems that
COX-2 induction involves NF-kB. Our investigations show that
cytoplasmic NF-kB-p65 protein (which is thought to be mostly in
its inactive, bound state) is present in small amounts in non-
neoplastic colorectal epithelial cells, while no endonuclear (un-
bound, active form) protein was detected in these cells. In contrast,
in malignant epithelial cells of the colon and rectum, there was a
distinct increase of both inactive (cytoplasmic) and potentially
active (endonuclear) NF-kB-p65. Thus in malignant colorectal
epithelial cells, both the expression of the NF-kB gene, as well as
the activation of the latent cytoplasmic protein to an active form
are increased. The intracellular, cytoplasmic concentration of IKKa
also tended to be expressed at increased levels in cancerous
colorectal epithelial cells. Furthermore, in tumour tissue the
expression of NF-kB-p65 was highly correlated with COX-2
immunohistochemistry. These observations are compatible with
the hypothesis that NF-kB is involved in COX-2 induction in these
tumours, and that NF-kB is probably activated by IKKa.
This is in agreement with many epidemiological studies, which
have demonstrated a 40–50% decrease in relative risk for
colorectal cancer in individuals taking nonsteroidal-antiinflamma-
tory drugs, compared to those not taking these agents. In addition,
several lines of experimental evidence indicate that NF-kB may
play an important role in the development and/or progression of
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Figure 2 Expression of COX-2, NF-kB and IKKa in matched normal and
malignant colonic epithelia from 24 patients. *Significantly different
(Wilcoxon’s signed rank test, Po0.03) from normal tissue.
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Figure 3 Expression of NF-kB and IKKa compared to COX-2 in
malignant colonic epithelia. Expression of NF-kB is highly correlated with
COX-2 expression (Pearson’s correlation, two-tailed P-value o0.005,
n¼30 patients). Values are mean7s.e.m.
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shuman cancers: (1) several members of the IkB and NF-kB families
derive from genes that are translocated or amplified in human
cancers (Bours et al, 2000). These genetic changes can all lead to
enhanced NF-kB transcription activity, indicating that NF-kB
target genes may be involved in the control of crucial steps for
cellular transformation and cancer progression (Bours et al, 2000).
(2) The v-rel oncogene of the reticuloendotheliosis virus T (Rev-
T), the first member of the Rel/NF-kB family to be discovered
(Gilmore, 1999; Bours et al, 2000), can directly transform cells in
vivo or in vitro. (3) More recently, NF-kB constitutive activity, as
observed in Hodgkin’s lymphoma cells, has been associated with a
mutation in the gene encoding the IkB-inhibitor (Krappmann et al,
1999), which can lead to impaired control of NF-kB activity and
hence to enhanced nuclear activity (Bours et al, 2000). The NF-kB
transcription factor is activated in response to a broad range of
preapoptotic stimuli (Osborn et al, 1989; Brach et al, 1991; Schreck
et al, 1991), dissociates from its attached inhibitory protein IkB
and translocates to the nucleus to induce the expression of target
genes, including several well-known antiapoptotic genes such as
TNF-receptor-associated factor 1 (TRAF1), and TRAF2, cIAPs,
manganese superoxide dismutase, A20 and IEX-IL (Wang et al,
1998; Wu et al, 1998).
Although NF-kB has been previously shown to be expressed at
high levels in human colonic adenomatous polyps, our investiga-
tions have demonstrated for the first time (to the best of our
knowledge) that IKKa, cytoplasmic inactive NF-kB-p65 protein
and putative active endonuclear NF-kB-p65 protein are signifi-
cantly increased in malignant colorectal epithelial cells. Our data
support the findings of many in vitro experiments and provide
evidence for a direct association between NF-kB and COX-2
induction in human tumours.
In summary, we have shown that intracellular levels of NF-kB-
p65 and IKKa are increased in malignant colorectal epithelial
cells, compatible with the hypothesis that NF-kB is involved
in COX-2 induction in these tumours, and possibly the activation
of other antiapoptotic genes that influence the development
of colorectal carcinogenesis. Finally, the lack of association
between NF-kB or COX-2 expression and Dukes’ stages
further suggests that NF-kB and COX-2 expressions are possibly
early postinitiation events that could be involved in tumour
progression.
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